![Johan Van Hoof](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christian Cardon | M | 56 |
Ziphius Vaccines NV
![]() Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | 5 years |
Olivier Lemaire | M | - |
Ziphius Vaccines NV
![]() Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Annie Vereecken | F | - |
Ziphius Vaccines NV
![]() Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Tom Almey | M | - |
Ziphius Vaccines NV
![]() Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Maria Hulsbosch | F | - |
P.J.A. Beheer
![]() P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | 21 years |
Griet Nuytinck | M | - |
Ziphius Vaccines NV
![]() Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Johan Van Hoof
- Personal Network